AU2003217925A1 - Treatment of metastatic institute for cancer - Google Patents

Treatment of metastatic institute for cancer

Info

Publication number
AU2003217925A1
AU2003217925A1 AU2003217925A AU2003217925A AU2003217925A1 AU 2003217925 A1 AU2003217925 A1 AU 2003217925A1 AU 2003217925 A AU2003217925 A AU 2003217925A AU 2003217925 A AU2003217925 A AU 2003217925A AU 2003217925 A1 AU2003217925 A1 AU 2003217925A1
Authority
AU
Australia
Prior art keywords
metastatic
cancer
institute
treatment
metastatic institute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003217925A
Inventor
Michael I. Ebright
Yuman Fong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2003217925A1 publication Critical patent/AU2003217925A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003217925A 2002-03-01 2003-03-03 Treatment of metastatic institute for cancer Abandoned AU2003217925A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36111702P 2002-03-01 2002-03-01
US60/361,117 2002-03-01
PCT/US2003/006659 WO2003073919A2 (en) 2002-03-01 2003-03-03 Treatment of metastatic institute for cancer

Publications (1)

Publication Number Publication Date
AU2003217925A1 true AU2003217925A1 (en) 2003-09-16

Family

ID=27789069

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003217925A Abandoned AU2003217925A1 (en) 2002-03-01 2003-03-03 Treatment of metastatic institute for cancer

Country Status (2)

Country Link
AU (1) AU2003217925A1 (en)
WO (1) WO2003073919A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2171071B1 (en) 2007-06-15 2015-08-05 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells

Also Published As

Publication number Publication date
WO2003073919A2 (en) 2003-09-12
WO2003073919A3 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2003226301A1 (en) Method of treating cancer
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
EP1613308A4 (en) Novel methods for the treatment of cancer
AUPS054702A0 (en) Cancer therapy
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
AU2002951346A0 (en) Diagnosis of ovarian cancer
AU2003256847A1 (en) Method of treating cancer
AU2003235618A1 (en) Ultrasonic treatment of breast cancer
AUPS273402A0 (en) Microwave treatment of ores
AU2003293333A1 (en) Method of treating cancers
AU2002328952A1 (en) Irinotecan for treatment of cancer
AU2003212634A1 (en) Compounds useful in the treatment of cancer
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003280558A1 (en) Method for treatment of cancer
AU2003222449A1 (en) Medicine for treating cancer
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003283339A1 (en) Cancer therapy determination
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003302625A1 (en) Silicon compounds useful in cancer therapy
GB0329416D0 (en) Treatment of cancer
AU2003217925A1 (en) Treatment of metastatic institute for cancer
AU2004281077A1 (en) Methods and agents for the treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase